Changes in lipid profiles after switching to a protease inhibitor-containing cART--unfavourable effect of fosamprenavir in obese patients.

about

[HIV infection : chronic disease with comorbidities].

P2860

Q38413754-77653A2A-FDFF-409E-871A-131FEBC6E08C

P2860

Changes in lipid profiles after switching to a protease inhibitor-containing cART--unfavourable effect of fosamprenavir in obese patients.

Item

http://www.wikidata.org/entity/Q35963960

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Changes in lipid profiles afte ...... samprenavir in obese patients.

@ast

Changes in lipid profiles afte ...... samprenavir in obese patients.

@en

type

Item

label

Changes in lipid profiles afte ...... samprenavir in obese patients.

@ast

Changes in lipid profiles afte ...... samprenavir in obese patients.

@en

prefLabel

Changes in lipid profiles afte ...... samprenavir in obese patients.

@ast

Changes in lipid profiles afte ...... samprenavir in obese patients.

@en

P1476

Changes in lipid profiles afte ...... samprenavir in obese patients.

@en

P2093

J R Bogner

http://www.w3.org/2001/XMLSchema#string

Miriam Gyalrong-Steur

http://www.w3.org/2001/XMLSchema#string

U Seybold

http://www.w3.org/2001/XMLSchema#string

P2860

European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constitute

A longitudinal analysis of the risk factors for diabetes and coronary heart disease in the Framingham Offspring Study

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

The metabolic syndrome--a new worldwide definition

Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

CD4+ count-guided interruption of antiretroviral treatment

Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras.

Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths.

P2888

2047-783x-16-2-85

P304

85-92

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/2047-783X-16-2-85

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1032295585

http://www.w3.org/2001/XMLSchema#string

P698

21463988

http://www.w3.org/2001/XMLSchema#string

P921

Adipositas

P932

3353428

http://www.w3.org/2001/XMLSchema#string

Changes in lipid profiles after switching to a protease inhibitor-containing cART--unfavourable effect of fosamprenavir in obese patients.

about

P2860

P2860

Changes in lipid profiles after switching to a protease inhibitor-containing cART--unfavourable effect of fosamprenavir in obese patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P6179

P698

P921

P932